Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mucossifa
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Mucossifa is a veterinary vaccine used in cattle for the prevention of viremia caused by infection with bovine viral diarrhea virus type 1 (BVDV-1). It is formulated as an inactivated viral vaccine to induce active immunity in bovines, reducing the risk and severity of BVDV-1 infection and its associated economic and health impacts on herds, such as immunosuppression, reproductive failure, and mucosal disease. The product is authorized for use in cattle with a defined onset of immunity following completion of the recommended vaccination schedule and is part of broader bovine respiratory and reproductive disease control programs.
- Brand names
- Mucossifa
Beyond the preview
Go deeper on Mucossifa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mucossifa.